The Evolving Biosimilar Landscape: Approval of the First Etanercept Biosimilar in Europe, An Interview With Emilio Martín-Mola - European Medical Journal

The Evolving Biosimilar Landscape: Approval of the First Etanercept Biosimilar in Europe, An Interview With Emilio Martín-Mola

Download PDF
*Caroline Charles

Professor Martín-Mola has received funding from Biogen, Roche, MSD, UCB, and Sanofi.


Biogen provided funding for medical writing support in the development of this article. Biogen reviewed the article for medical accuracy and provided feedback to the authors. All named authors had full editorial control of the paper, and provided their final approval of all the content.

EMJ. ;1[3]:76-84. DOI/10.33590/emj/10314707.
Biosimilars, biologics, disease-modifying anti-rheumatic drugs (DMARDs), SB4 (Benepali®), entanercept (Enbrel®), rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondylitis, plaque psoriasis (PP), European Medicines Agency (EMA)

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


On January 14th 2016, SB4 (Benepali®) received marketing authorisation application approval from the European Commission (EC). It is the first biosimilar to etanercept available in Europe as well as the first subcutaneous anti-tumour necrosis factor biosimilar. Benepali® was approved for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic spondyloarthritis), and plaque psoriasis.

SB4 adds to the available biologic armamentarium of biosimilars in rheumatology, which also includes two infliximab biosimilars; one under the brand names Remsima® and Inflectra®, and the other under the brand name Flixabi®. Unlike infliximab biosimilar, which is a chimeric monoclonal antibody, SB4 is a fusion protein.

We aimed to review the current European Medicines Agency (EMA) requirements for the approval of biosimilars and how these products can integrate into daily clinical practice in rheumatology.

To that effect, we recently discussed with Dr Emilio Martín-Mola about the European framework for approval of biosimilars and the controversies that may surround this new category of medicinal products. We discussed how the advent of biosimilars in rheumatology has the potential to truly be a game-changer for both physicians and patients.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now